105 related articles for article (PubMed ID: 8284832)
21. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
Yéléhé-Okouma M; Martini H; Lemarié J; Labroca P; Petitpain N; Gibaja V; Paille F; Gillet P
Fundam Clin Pharmacol; 2017 Oct; 31(5):574-579. PubMed ID: 28322465
[TBL] [Abstract][Full Text] [Related]
22. Naltrexone for the treatment of alcoholism.
Ciraulo AM; Alpert N; Franko KJ
Am Fam Physician; 1997 Sep; 56(3):803-6. PubMed ID: 9301573
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K
Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
[TBL] [Abstract][Full Text] [Related]
25. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
Kaplan JL; Marx JA; Calabro JJ; Gin-Shaw SL; Spiller JD; Spivey WL; Gaddis GM; Zhao N; Harchelroad FP
Ann Emerg Med; 1999 Jul; 34(1):42-50. PubMed ID: 10381993
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
[TBL] [Abstract][Full Text] [Related]
27. Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators.
Clark WM; Raps EC; Tong DC; Kelly RE
Stroke; 2000 Jun; 31(6):1234-9. PubMed ID: 10835438
[TBL] [Abstract][Full Text] [Related]
28. Naltrexone: new preparation. Transient preventive efficacy on alcoholic relapse.
Prescrire Int; 1999 Feb; 8(39):9-11. PubMed ID: 10557566
[TBL] [Abstract][Full Text] [Related]
29. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
30. Nalmefene--a long-acting injectable opioid antagonist.
Med Lett Drugs Ther; 1995 Oct; 37(960):97-8. PubMed ID: 7565300
[No Abstract] [Full Text] [Related]
31. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD
Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538
[TBL] [Abstract][Full Text] [Related]
32. Historical perspective on the chemistry and development of naltrexone.
Archer S
NIDA Res Monogr; 1981; 28():3-10. PubMed ID: 6791011
[TBL] [Abstract][Full Text] [Related]
33. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study.
Lubin G; Weizman A; Shmushkevitz M; Valevski A
Hum Psychopharmacol; 2002 Jun; 17(4):181-5. PubMed ID: 12404685
[TBL] [Abstract][Full Text] [Related]
34. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
[TBL] [Abstract][Full Text] [Related]
35. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users.
Hulse GK; Tait RJ
Addict Biol; 2003 Sep; 8(3):337-42. PubMed ID: 13129836
[TBL] [Abstract][Full Text] [Related]
36. [Interactions between naltrexone, an opioid antagonist, and opioids administered during general anesthesia].
Tesson B; Bigot-Viale A; Vigue JP; Pierrot M; Granry JC
Ann Fr Anesth Reanim; 1999 Feb; 18(2):230-2. PubMed ID: 10207596
[TBL] [Abstract][Full Text] [Related]
37. Nalmefene hydrochloride.
Chumpa A
Pediatr Emerg Care; 1999 Apr; 15(2):141-3. PubMed ID: 10220088
[No Abstract] [Full Text] [Related]
38. Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures.
Barsan WG; Seger D; Danzl DF; Ling LJ; Bartlett R; Buncher R; Bryan C
Am J Emerg Med; 1989 Mar; 7(2):155-61. PubMed ID: 2645889
[TBL] [Abstract][Full Text] [Related]
39. Naltrexone and nalmefene: any meaningful difference?
Swift RM
Biol Psychiatry; 2013 Apr; 73(8):700-1. PubMed ID: 23540350
[No Abstract] [Full Text] [Related]
40. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling.
Grant JE; Kim SW; Hollander E; Potenza MN
Psychopharmacology (Berl); 2008 Nov; 200(4):521-7. PubMed ID: 18581096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
